FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Mitrani Albert
2. Issuer Name and Ticker or Trading Symbol

Biotech Products Services & Research, Inc. [ BPSR ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
CEO, Pres., Sec'y & Treas.
(Last)          (First)          (Middle)

4045 SHERIDAN AVE., SUITE 239
3. Date of Earliest Transaction (MM/DD/YYYY)

11/1/2016
(Street)

MIAMI, FL 33140
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   11/1/2016     J/K (1)    100000   D $0   74005190   D    
Common Stock   11/1/2016     J/K (2)    20000000   D $0   54005190   D    
Series A Non-Convertible Preferred Stock   11/1/2016     J/K (5)    100000   A $0   100000   D    
Common Stock                  10000000   I   By Spouse   (6)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Convertible Preferred Stock   $0   11/1/2016     J/K   (3)    1000000       11/1/2016     (4) Common Stock   20000000   $0   1000000   D    

Explanation of Responses:
(1)  On November 1, 2016, the Issuer entered into a Share Exchange Agreement with Albert Mitrani pursuant to which Mr. Mitrani exchanged 100,000 shares of his Common Stock of the Company for 100 shares of Series A Non-Convertible Preferred Stock of the Company pursuant to Section 3(a)(9) of the Securities Act.
(2)  On November 1, 2016, the Issuer entered into a Share Exchange Agreement with Mr. Mitrani pursuant to which Mr. Mitrani exchanged 20 million (20,000,000) shares of his Common Stock of the Company for an aggregate of 1 million (1,000,000) shares Series B Convertible Preferred Stock of the Company pursuant to Section 3(a)(9) of the Securities Act.
(3)  Each share Series B Convertible Preferred Stock is convertible into Twenty (20) shares of Common Stock, at any time and from time to time upon the election of the holder thereof.
(4)  No expiration date.
(5)  The Series A Non-Convertible Preferred Stock shall vote together with the shares of Common Stock and other voting securities of the Company as a single class and, regardless of the number of shares of Series A Non-Convertible Preferred Stock outstanding, and as long as at least one share of Series A Non-Convertible Preferred Stock is outstanding, such shares shall represent eighty percent (80%) of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders. Each outstanding share of the Series A Non-Convertible Preferred Stock shall represent its proportionate share of the 80% which is allocated to the outstanding shares of Series A Non-Convertible Preferred Stock.
(6)  On November 4, 2016, the Issuer issued Dr. Maria I. Mitrani, Mr. Mitrani's wife, a warrant to purchase up to 10,000,000 shares of Common Stock of the Issuer for $0.06 per share from the date of issuance until the tenth anniversary of the date of issuance. The warrant was issued in connection with Dr. Mitrani's employment agreement with the Company, dated November 4, 2016.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Mitrani Albert
4045 SHERIDAN AVE.
SUITE 239
MIAMI, FL 33140
X X CEO, Pres., Sec'y & Treas.

Signatures
Albert Mitrani 11/21/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.